"Desire to designate and support specialized centers to improve pulmonary hypertension survival rates"
Aug 04, 2024
Development directions for improving the survival rate of pulmonary hypertension patients in Korea were suggested.
The Korean Society of Pulmonary Hypertension, where Professor Jung Wook-jin of Cardiology at Gachon University Gil Hospital (Director of the Center for Cardiac Failure/Pulmonary Hypertension), is serving as the chairman, recently held a conference in Seoul Dragon City 'The 9th Korean Society of Pulmonary Hypertension and the 4th East Asian Society of Pulmonary Hypertension (PH Korea 2024 with 4th EASOPH)'.
Pulmonic Hypertension (PH) is an incurable disease that occurs in 1% of the world's population. It is estimated that there are about 500,000 patients with pulmonary hypertension in Korea and about 6,000 patients with pulmonary arterial hypertension. The five-year survival rate in Korea is about 72%, and the average survival period is 13.1 years, which has improved significantly compared to the past. However, more efforts are still needed compared to the survival rate of pulmonary arterial hypertension in advanced countries such as Japan reaching more than 85%.
Under the theme of "'Pulmonary Hypertension, Know in advance, Treat Properly, and Stay Happy!'", more than 500 experts, including 93 foreigners, from 23 countries, including four Asian countries, Japan, China, and Taiwan, participated in the conference. At the conference, medical staff from various fields, including cardiology, pediatrics, rheumatology, and respiratory medicine, discussed multidisciplinary treatment, and in joint sessions with the Korean Society of Vascularization (KOVAS) and the Korean Society of Cardiac Failure (KSHF), a multifaceted approach to pulmonary hypertension was taken.
During this academic conference, a meeting was held on the theme of 「Doctors, governments, and patient cooperation measures to improve the survival rate of pulmonary hypertension in Korea」. ▲ Policy suggestions for the professional treatment of pulmonary hypertension in Korea ▲ 'Family Hope Campaign' to improve disease awareness ▲ 'OPUS-K' research plan proposal to overcome ultimate pulmonary hypertension was discussed in this meeting.
Kim Dae-hee, policy director of the Korean Pulmonary Hypertension Association, emphasized the government's active support for the introduction of new drugs', 'health insurance benefits', and 'establishment of a specialized center'.
Policy Director Kim Dae-hee "We expect that the introduction of treatments actively used overseas will change the game of pulmonary arterial hypertension treatment options in Korea, which have only been controlling symptoms.""It is also necessary to quickly provide pulmonary arterial hypertension drugs for newborns and children " he said.
He then added, `It is difficult to find a hospital with a multidisciplinary team, let alone a pulmonary hypertension prescription center in Korea, so the government's interest in designating a pulmonary hypertension center is desperate.'
In addition, Chairman Jung Wook-jin (Cardiology at Gachon University Gil Hospital) proposed a project to overcome pulmonary hypertension using electric precision medicine (OPUS-K, tentatively named) to fundamentally overcome pulmonary hypertension, an incurable disease. The project aims to increase the survival rate of pulmonary hypertension in Korea to the highest in the world by raising the compliance rate of pulmonary hypertension treatment guidelines in Korea to the level of developed countries. There are four major tasks: ▲ Diagnostic biomarkers and treatment targets discovery brokerage research ▲ Establishment of an international cooperation system for precision medicine ▲ Randomized clinical research to create evidence ▲ Implementation research to improve compliance with medical guidelines.
Chairman Jung Wook-jin expects this project to improve the 5-year survival rate of pulmonary hypertension, which lags behind advanced countries such as the U.S., U.K., and Japan, by more than 95%, especially in patients with pulmonary hypertension"As pulmonary arterial hypertension patients in Korea can expect a survival rate of more than 70% at early diagnosis, we hope that OPUS-K to strengthen their expertise in early diagnosis, treatment, and management will be included in the government's mid- to long-term research projects such as K-ARPA-H for continuous support."
The society is also developing a 'Lung, Family Hope Campaign' for the public to improve awareness of pulmonary hypertension diseases. Public relations director Kim Kyung-hee said, `Lung, Hope Campaign is an activity for early detection and treatment through accurate diagnosis.' As part of the campaign project, educational materials on the diagnosis and treatment of pulmonary hypertension for medical staff are developed, distributed and educated, and educational videos of public education are produced to enhance patients' understanding of the disease and to visit appropriate hospitals, and spread through academic societies and YouTube," he said.
He then added that "The society will continue its campaign activities to provide accurate information on the disease.'
Meanwhile, the Korean Society of Pulmonary Hypertension was launched in 2017 as a pulmonary hypertension research group under the Korean Society of Hypertension. The society is carrying out activities to promote the importance of early diagnosis, treatment, and management by improving awareness, such as 'Lung and Family Hope Campaign'. In addition, since 2018, it has been conducting a long-term follow-up study 'PHOENIKS' with the Cardiovascular Disease Division of the National Health Center of the Korea Centers for Disease Control and Prevention. In 2023, it has compiled a Korean pulmonary hypertension textbook with 58 faculty members across the country and will establish a domestic pulmonary hypertension guideline based on the latest global practice guideline '2022 ESC/ERS Guidelines'.
The Korean Society of Pulmonary Hypertension, where Professor Jung Wook-jin of Cardiology at Gachon University Gil Hospital (Director of the Center for Cardiac Failure/Pulmonary Hypertension), is serving as the chairman, recently held a conference in Seoul Dragon City 'The 9th Korean Society of Pulmonary Hypertension and the 4th East Asian Society of Pulmonary Hypertension (PH Korea 2024 with 4th EASOPH)'.
Pulmonic Hypertension (PH) is an incurable disease that occurs in 1% of the world's population. It is estimated that there are about 500,000 patients with pulmonary hypertension in Korea and about 6,000 patients with pulmonary arterial hypertension. The five-year survival rate in Korea is about 72%, and the average survival period is 13.1 years, which has improved significantly compared to the past. However, more efforts are still needed compared to the survival rate of pulmonary arterial hypertension in advanced countries such as Japan reaching more than 85%.
Under the theme of "'Pulmonary Hypertension, Know in advance, Treat Properly, and Stay Happy!'", more than 500 experts, including 93 foreigners, from 23 countries, including four Asian countries, Japan, China, and Taiwan, participated in the conference. At the conference, medical staff from various fields, including cardiology, pediatrics, rheumatology, and respiratory medicine, discussed multidisciplinary treatment, and in joint sessions with the Korean Society of Vascularization (KOVAS) and the Korean Society of Cardiac Failure (KSHF), a multifaceted approach to pulmonary hypertension was taken.
During this academic conference, a meeting was held on the theme of 「Doctors, governments, and patient cooperation measures to improve the survival rate of pulmonary hypertension in Korea」. ▲ Policy suggestions for the professional treatment of pulmonary hypertension in Korea ▲ 'Family Hope Campaign' to improve disease awareness ▲ 'OPUS-K' research plan proposal to overcome ultimate pulmonary hypertension was discussed in this meeting.
Kim Dae-hee, policy director of the Korean Pulmonary Hypertension Association, emphasized the government's active support for the introduction of new drugs', 'health insurance benefits', and 'establishment of a specialized center'.
Policy Director Kim Dae-hee "We expect that the introduction of treatments actively used overseas will change the game of pulmonary arterial hypertension treatment options in Korea, which have only been controlling symptoms.""It is also necessary to quickly provide pulmonary arterial hypertension drugs for newborns and children " he said.
He then added, `It is difficult to find a hospital with a multidisciplinary team, let alone a pulmonary hypertension prescription center in Korea, so the government's interest in designating a pulmonary hypertension center is desperate.'
In addition, Chairman Jung Wook-jin (Cardiology at Gachon University Gil Hospital) proposed a project to overcome pulmonary hypertension using electric precision medicine (OPUS-K, tentatively named) to fundamentally overcome pulmonary hypertension, an incurable disease. The project aims to increase the survival rate of pulmonary hypertension in Korea to the highest in the world by raising the compliance rate of pulmonary hypertension treatment guidelines in Korea to the level of developed countries. There are four major tasks: ▲ Diagnostic biomarkers and treatment targets discovery brokerage research ▲ Establishment of an international cooperation system for precision medicine ▲ Randomized clinical research to create evidence ▲ Implementation research to improve compliance with medical guidelines.
Chairman Jung Wook-jin expects this project to improve the 5-year survival rate of pulmonary hypertension, which lags behind advanced countries such as the U.S., U.K., and Japan, by more than 95%, especially in patients with pulmonary hypertension"As pulmonary arterial hypertension patients in Korea can expect a survival rate of more than 70% at early diagnosis, we hope that OPUS-K to strengthen their expertise in early diagnosis, treatment, and management will be included in the government's mid- to long-term research projects such as K-ARPA-H for continuous support."
The society is also developing a 'Lung, Family Hope Campaign' for the public to improve awareness of pulmonary hypertension diseases. Public relations director Kim Kyung-hee said, `Lung, Hope Campaign is an activity for early detection and treatment through accurate diagnosis.' As part of the campaign project, educational materials on the diagnosis and treatment of pulmonary hypertension for medical staff are developed, distributed and educated, and educational videos of public education are produced to enhance patients' understanding of the disease and to visit appropriate hospitals, and spread through academic societies and YouTube," he said.
He then added that "The society will continue its campaign activities to provide accurate information on the disease.'
Meanwhile, the Korean Society of Pulmonary Hypertension was launched in 2017 as a pulmonary hypertension research group under the Korean Society of Hypertension. The society is carrying out activities to promote the importance of early diagnosis, treatment, and management by improving awareness, such as 'Lung and Family Hope Campaign'. In addition, since 2018, it has been conducting a long-term follow-up study 'PHOENIKS' with the Cardiovascular Disease Division of the National Health Center of the Korea Centers for Disease Control and Prevention. In 2023, it has compiled a Korean pulmonary hypertension textbook with 58 faculty members across the country and will establish a domestic pulmonary hypertension guideline based on the latest global practice guideline '2022 ESC/ERS Guidelines'.
|
bellho@sportschosun.com
